ResearchAndMarkets.com added separate reports on Europe’s alpha-emitting radioligand therapy market and France’s broader radiopharmaceuticals and theranostics market. Europe’s alpha-emitting segment is projected to grow from approximately USD 0.05 billion currently to nearly USD 0.40 billion by 2035 at close to 26% annually, while France’s overall market is estimated at USD 447 million currently and forecast to reach USD 1,032.8 million at approximately 9.8% annual growth. Expansion is supported by prostate cancer and neuroendocrine tumor demand, clinical development of actinium-225, lead-212 and lutetium-177 therapies, wider reimbursement, nuclear medicine infrastructure and domestic isotope-production investment. Radium-223 remains the principal established alpha-emitting therapy, while most newer candidates remain investigational. France is strengthening its role in the regional supply chain through Curium and Orano Med projects, including a more than €32 million lutetium-177 production line, a €250 million thorium-extraction facility and a lead-212 ATLab supported by a €125 million European Investment Bank credit line.